Harbour Biomed announced license agreement with AZ for Claudin18.2 targeting bispecific antibody
Harbour BioMed announced a global out-license agreement with AstraZeneca for CLDN18.2xCD3 bispecific antibody HBM7022, a novel bispecific antibody generated from HBM's HCAb Based Immune Cell Engagers (HBICE) Platform. This license agreement and recognition by an industry-leading global biopharmaceutical company marks a major milestone in HBM's business development, validating the potential of the Company's technology platform and innovation capabilities. HBM7022 is a bispecific antibody, currently in pre-clinical stage, that crosslinks tumor cells and T cells by targeting a tumor-associated antigen (Claudin18.2) and CD3, and thus leads to potent T cell activation and tumor elimination. AstraZeneca will be granted an exclusive global license for research, development, registration, manufacturing, and commercialization of HBM7022 and shall be solely responsible for all costs and activities associated with its further development and commercialization. HBM shall receive an upfront payment of $25 million with the potential for additional payments up to $325 million pending achievement of certain development, regulatory and commercial milestones. HBM is also eligible to receive tiered royalties on net sales.
Pregene entered into innovative partnership with CellPoint to develop anti-BCMA CAR-T
Shenzhen Pregene Biopharma and CellPoint announced an exclusive license agreement for the development and commercialization of PRG-1801, Pregene's single domain antibody-based anti-BCMA CAR-T program, for the treatment of hematological indications in Europe and US. PRG-1801 is a single domain antibody anti-BCMA CAR-T cell therapy in development for the treatment of relapsed/refractory multiple myeloma that has demonstrated strong signs of efficacy and an excellent safety profile in its initial investigator-initiated trial and Phase 1/2 trials. Pregene will receive over €20 million of upfront and near-term consideration, and is eligible to receive additional development, commercial milestone, and royalty payments. CellPoint will be responsible for the development and commercialization of the anti-BCMA CAR-T therapy in Europe and the US. As part of this partnership, Pregene will also provide translational and lentivirus manufacturing services to be reimbursed by Cellpoint.